Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TCF4 | P15884 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598188 | 0.88 | TRPV1 (0.51) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL3793148 | 0.88 | TRPV1 (0.51) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL8222368 | 0.87 | TRPV1 (0.50) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL1672629 | 0.85 | AKR1C3 (0.56) | RAB9APOLBNPC1MAPTHIF1A | |
| SCHEMBL11073671 | 0.84 | EGFR (0.54) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL25174147 | 0.80 | RAB9A (0.59) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL30445248 | 0.80 | RAB9A (0.59) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL23518403 | 0.78 | RAB9A (0.59) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL3598973 | 0.78 | SMN1; SMN2 (0.50) | MAPK1RAB9APOLBALDH1A1NPC1 | |
| SCHEMBL8672958 | 0.77 | RAB9A (0.60) | EGFRMAPK1HSD17B10RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010086454-A9 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010086454-A9 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010086454-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086454-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2010-08-05 | — | — | WO | disclosed |
| EP-2213286-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | Zeltia, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213286-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | Zeltia, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| WO-2008015240-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PNMT, PSEN1, SNCA | EGFR 4287/4885MAPK1 724/4885HSD17B10 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.